Invokana Development Directed By Mechanism Of Action
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
J&J’s canagliflozin is the first approval for a new pharmacologic approach to diabetes treatment, so FDA and the sponsor looked closely at the mechanism of action to identify safety questions – and to structure a clinical program that would provide data to answer them in the first review cycle.